Nexturn Bioscience

Nexturn Bioscience is a South Korea-listed company that historically manufactured CNC automatic lathes and later expanded into bio/healthcare, IT, investment, and consulting. Its healthcare exposure appears to be driven primarily through subsidiary and investment activities, especially Nexturn Bio and RosVivo Therapeutics, rather than through a large standalone in-house drug pipeline. Public disclosures and press coverage link the group to miRNA-based therapeutics for diabetes and obesity, including the RosVivo program RSVI-301, and to medical robot technology initiatives. The company also completed an absorption merger of wholly owned subsidiary Nexturn Bio in 2025. Overall, Nexturn Bioscience should be viewed as a diversified listed company with an emerging but relatively limited biotech/healthcare footprint centered on RNA therapeutics investments.